Key result
MYBPC3 25-bp deletion linked to a ~4-fold higher risk of reduced LVEF in CAD.
Why the study?
The frequency of MYBPC3 25 bp deletion and its association with left ventricular dysfunction in CAD patients had not been established in an unrelated cohort.
Case-Control (n=625)
No
Odds Ratio: 4.32 (95% CI 1.58–11.82)
Absolute Event Rate: 15.3% vs 3.9%
p-value: p=0.004
May flag higher-risk CAD patients; leaves open causal role and need for replication before any clinical use.
RATIONALE: Mutations in MYBPC3 encoding cardiac myosin binding protein C are common genetic cause of hereditary cardiac myopathies. An intronic 25-bp deletion in MYBPC3 at 3' region is associated with dilated (DCM) and hypertrophic (HCM) cardiomyopathies in Southeast Asia. However, the frequency of MYBPC3 25 bp deletion and associated clinical presentation has not been established in an unrelated cohort of left ventricular dysfunction (LVD) secondary to coronary artery disease (CAD) patients. OBJECTIVE: We sought to determine the role of MYBPC3 25 bp polymorphism on LVD in two cohorts of CAD patients. METHODS AND RESULTS: The study included 265 consecutive patients with angiographically confirmed CAD and 220 controls. MYBPC3 25 bp polymorphism was determined by polymerase chain reaction. Our results showed that carrier status of MYBPC3 25 bp deletion was associated with significant compromised left ventricle ejection fraction (LVEF ≤45) in CAD patients (p value = <0.001; OR = 4.49). To validate our results, we performed a replication study in additional 140 cases with similar clinical characteristics and results again confirmed consistent findings (p = 0.029; OR = 3.3). Also, presence of the gene deletion did not have significant association in CAD patients with preserved ejection fraction (LVEF>45) (p value = 0.1; OR = 2.3). CONCLUSION: The frequency of MYBPC3 DW genotype and D allele was associated with compromised LVEF implying that genetic variants of MYBPC3 encoding mutant structural sarcomere protein could increase susceptibility to left ventricular dysfunction. Therefore, 25 bp deletion in MYBPC3 may represent a genetic marker for cardiac failure in CAD patients from Southeast Asia.
No takes yet. Share an insight, caveat, or question.
Srivastava et al. (2011) conducted a case-control in Coronary Artery Disease with Left Ventricular Dysfunction (n=625). MYBPC3 25 bp deletion vs. Wild type (no deletion) was evaluated on Compromised left ventricle ejection fraction (LVEF ≤45%) (OR 4.32, 95% CI 1.58-11.82, p=0.004). Carrier status of the MYBPC3 25 bp deletion was significantly associated with compromised left ventricular ejection fraction in patients with coronary artery disease (OR 4.32).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: